Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2116–2119. doi: 10.1128/aac.39.9.2116

In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.

A M Dhople 1, M A Ibanez 1
PMCID: PMC162891  PMID: 8540726

Abstract

The in vitro susceptibility of Mycobacterium leprae to levofloxacin was studied by using two biochemical parameters to measure the metabolic activity of the organism. Levofloxacin consistently exhibited twofold greater bactericidal activity than ofloxacin, with the MIC being 0.75 microgram/ml. When combined with one of the three rifamycin analogs, synergism was obtained with KRM-1648 and rifabutin but not with rifampin.

Full Text

The Full Text of this article is available as a PDF (177.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckers B., Lang H. R., Schimke D., Lammers A. Evaluation of a bioluminescence assay for rapid antimicrobial susceptibility testing of mycobacteria. Eur J Clin Microbiol. 1985 Dec;4(6):556–561. doi: 10.1007/BF02013394. [DOI] [PubMed] [Google Scholar]
  2. Dhople A. M., Green K. J., Osborne L. J. Limited in vitro multiplication of Mycobacterium leprae. Ann Inst Pasteur Microbiol. 1988 Mar-Apr;139(2):213–223. doi: 10.1016/0769-2609(88)90006-3. [DOI] [PubMed] [Google Scholar]
  3. Dhople A. M., Hanks J. H. In vitro growth of Mycobacterium lepraemurium, an obligate intracellular microbe. Science. 1977 Jul 22;197(4301):379–381. doi: 10.1126/science.327548. [DOI] [PubMed] [Google Scholar]
  4. Dhople A. M., Ibanez M. A., Gardner G. D. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae. Arzneimittelforschung. 1993 Mar;43(3):384–386. [PubMed] [Google Scholar]
  5. Dhople A. M., Ibanez M. A. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. Arzneimittelforschung. 1994 Apr;44(4):563–565. [PubMed] [Google Scholar]
  6. Dhople A. M., Ibanez M. A. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae. J Antimicrob Chemother. 1995 Apr;35(4):463–471. doi: 10.1093/jac/35.4.463. [DOI] [PubMed] [Google Scholar]
  7. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grosset J. H., Guelpa-Lauras C. C., Perani E. G., Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988 Jun;56(2):259–264. [PubMed] [Google Scholar]
  9. Grosset J. H., Ji B. H., Guelpa-Lauras C. C., Perani E. G., N'Deli L. N. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281–295. [PubMed] [Google Scholar]
  10. Hallander H. O., Dornbusch K., Gezelius L., Jacobson K., Karlsson I. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother. 1982 Nov;22(5):743–752. doi: 10.1128/aac.22.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heifets L. B., Lindholm-Levy P. J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. doi: 10.1016/0041-3879(87)90067-5. [DOI] [PubMed] [Google Scholar]
  12. Ji B., Grosset J. H. Recent advances in the chemotherapy of leprosy. Lepr Rev. 1990 Dec;61(4):313–329. doi: 10.5935/0305-7518.19900029. [DOI] [PubMed] [Google Scholar]
  13. Khanolkar S. R., Ambrose E. J., Chulawala R. G., Bapat C. V. Autoradiographic and metabolic studies of Mycobacterium leprae. Lepr Rev. 1978 Sep;49(3):187–198. [PubMed] [Google Scholar]
  14. Mor N., Vanderkolk J., Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161–1164. doi: 10.1128/aac.38.5.1161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Noordeen S. K. Elimination of leprosy as a public health problem. Indian J Lepr. 1994 Jan-Mar;66(1):1–10. [PubMed] [Google Scholar]
  16. Tomioka H., Saito H. Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice. Int J Lepr Other Mycobact Dis. 1993 Jun;61(2):250–254. [PubMed] [Google Scholar]
  17. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis. 1985 Mar;131(3):348–351. doi: 10.1164/arrd.1985.131.3.348. [DOI] [PubMed] [Google Scholar]
  18. Young L. S., Berlin O. G., Inderlied C. B. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med. 1987 Apr 27;82(4A):23–26. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES